Project Grant F32AI186477
- The University of California, Davis received a $3,161,373 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant, awarded on July 22, 2025, will support research to examine the transmission dynamics and fitness of the reemerging St. Louis encephalitis virus (SLEV) in mosquito vectors and West Nile virus (WNV) naive and immune avian reservoirs. The research aims to...
- The National Science Foundation (NSF) awarded a 5-year, $977,779 Project Grant under the Biological Sciences (CFDA 47.074) program to the University of California, Santa Barbara (UCSB) to investigate how climate change and land use shifts may impact the synchronization between mosquito vectors and bird hosts, and the implications for West Nile Virus transmission. The research will leverage a combination of modeling, causal inference, citizen science, and field data collection to understand how...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $155,454 to The Washington University to conduct research on the "Molecular Basis of Receptor Interactions for Venezuelan Equine Encephalitis" over a 2-year period from August 1, 2025 to July 31, 2027. The key objectives are to: Identify alternative entry receptors for the Venezuelan equine encephalitis virus (VEEV) using a novel...
- This Project Grant award of $651,084, made by the National Science Foundation (NSF) Biological Sciences program (CFDA 47.074), supports research to determine how microbes influence the response of their mosquito host to climate change, with a focus on the impacts on Hawaiian honeycreepers, an endangered bird species. The research aims to: Clarify the landscape-scale population dynamics of the mosquito vector Culex quinquefasciatus and its microbiome across an elevational gradient in Hawaii....
- This $611,861 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to characterize chromosomal rearrangements in the Aedes aegypti mosquito, which transmits diseases like dengue and Zika fever. The 5-year project, commencing on September 1, 2025, aims to determine if these rearrangements are subspecies-specific, associated with ecological factors in Africa, and involved in mosquito...
- This Project Grant award of $392,500.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports a research program at Arizona State University (ASU) focused on improving the understanding of cross-species viral transmission from wild mammals to humans. The key objectives of the five-year project are to: 1) develop automated tools to curate and maintain up-to-date taxonomic data on mammal and virus species, 2) test...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is focused on understanding the underlying mechanisms that allow bats to host viruses that cause high mortality in humans, such as rabies, Hendra, Nipah, Ebola, and SARS. The $455,692 award will enable experimental evolution studies on vesicular stomatitis virus (VSV) in bat cell lines to test theoretical predictions about how...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $254,250 to New York University (NYU) to investigate how alphaviruses, a group of mosquito-transmitted human pathogens, infect microvascular endothelial cells and how these cells respond to infection. The research aims to identify viral and host factors that restrict alphavirus infection in microvascular endothelial cells at multiple stages...
- This Project Grant award of $695,801 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to investigate the evolution and spread of the invasive mosquito Anopheles stephensi and its interactions with local Plasmodium falciparum malaria strains in Africa. The key objectives are to: 1) Evaluate the genomic adaptations enabling the spread and establishment of A. stephensi in Africa,...
- This National Science Foundation (NSF) Project Grant award, funded under the Social, Behavioral, and Economic Sciences program (CFDA 47.075), aims to investigate the role of human behavior in the dynamics of mosquito-borne diseases such as dengue and Zika. The $100,000 grant, awarded to North Carolina State University (NC State), will support a multidisciplinary research project to understand how individual decision-making around mosquito prevention behaviors impacts disease transmission. The...
TRANSMISSION DYNAMICS AND FITNESS OF REEMERGING ST. LOUIS ENCEPHALITIS VIRUS IN MOSQUITO VECTORS AND WEST NILE VIRUS NATIVE AND IMMUNE AVIAN RESERVOIRS - PROJECT SUMMARY/ABSTRACT: ST. LOUIS ENCEPHALITIS VIRUS (SLEV) IS A MOSQUITO-BORNE FLAVIVIRUS THAT CAUSES FEBRILE ILLNESS AND RARE FATAL ENCEPHALITIS IN HUMANS. SLEV BECAME ENDEMIC IN CALIFORNIA (CA) IN THE 1940'S, BUT BETWEEN 2003 AND 2014, NO HUMAN CASES NOR MOSQUITO ISOLATIONS WERE RECORDED IN CA, DEMONSTRATING AN SLEV REGIONAL EXTINCTION. IN 2003, A CLOSELY RELATED FLAVIVIRUS, WEST NILE VIRUS (WNV), ENTERED CA AND OTHER WESTERN STATES LEADING TO 7,597 CASES IN HUMANS (2003-2022) AND FATAL NEUROLOGIC DISEASE IN HORSES AND WILD BIRDS. LATER IN 2015, CONTEMPORARY SLEV STRAINS (CSLEV) TRACED TO SOUTH AMERICA EMERGED IN THE WESTERN US AND HAS SINCE BEEN DETECTED IN HUMANS AND CULEX MOSQUITOES THROUGHOUT CA IN EVERY SUBSEQUENT YEAR DESPITE CONTINUED WNV PRESENCE. THE REASONS FOR THE 11-YEAR HIATUS OF HISTORICAL SLEV STRAINS (HSLEV) FROM CA AND CSLEV EXPANSION SINCE 2015 REMAINS UNCHARACTERIZED. OUR EXPERIMENTAL STUDIES SHOW THAT HOUSE SPARROWS (PASSER DOMESTICUS), A KNOWN AVIAN RESERVOIR HOST SPECIES FOR WNV AND SLEV, WILL NOT MOUNT HSLEV VIREMIA AFTER DEVELOPING NEUTRALIZING ANTIBODIES FOR WNV, SUGGESTING THAT HSLEV WAS DISPLACED PRIMARILY BY WNV AVIAN HERD IMMUNITY. ADDITIONALLY, OUR PRELIMINARY DATA SHOW THAT SERUM FROM BIRDS INOCULATED WITH WNV POORLY NEUTRALIZE CSLEV STRAINS IN VITRO. GIVEN THESE FINDINGS, OUR CENTRAL HYPOTHESIS FOR THIS PROPOSAL IS THAT HSLEV STRAINS WERE LIKELY "OUT-COMPETED" IN AVIAN RESERVOIR HOSTS BY CROSS- PROTECTIVE WNV DERIVED HUMORAL (ANTIBODY-MEDIATED) IMMUNITY, AND THAT CSLEV STRAINS ESCAPE WNV AVIAN HOST IMMUNITY SUCH THAT INFECTION WITH WNV DOES NOT CONFER CROSS-PROTECTION AGAINST CSLEV INFECTION. TO UNDERSTAND DRIVERS OF SLEV REEMERGENCE, THE GOAL OF THIS PROJECT IS TO IDENTIFY HOW CHANGING SLEV-VECTOR- AVIAN HOST INTERACTIONS AND CROSS-PROTECTION BY WNV PROMOTE SLEV REEMERGENCE. TO TEST OUR HYPOTHESIS, WE PROPOSE A SET OF EXPERIMENTS TO INVESTIGATE 1) TRANSMISSION COMPETENCE AND FITNESS OF CSLEV VERSUS HSLEV IN CULEX MOSQUITOES, AND 2) AVIAN FITNESS, ANTIBODY KINETICS, AND ANTIBODY-MEDIATED PROTECTION FOR AND BETWEEN CSLEV, HSLEV, AND WNV IN HOUSE SPARROWS. THE FIRST AIM WILL USE TWO PRIMARY VECTORS IN CA, CULEX QUINQUEFASCIATUS, AND TARSALIS FOR ASSESSING VIRAL TITERS IN TISSUES AND SALIVA, AND TIME TO DISSEMINATION AND TRANSMISSION IN MOSQUITOES THAT INGEST DIFFERENT DOSES OF SLEV-SPIKED BLOODMEALS. NEXT, MOSQUITOES WILL BE CHALLENGED VIA MIXED INFECTION WITH CONTEMPORARY SLEV AND AN INFECTIOUS CLONE COMPETITOR MADE FROM HISTORIC OR CONTEMPORARY SLEV TO ASSESS RELATIVE FITNESS. IN THE SECOND AIM, WE WILL INOCULATE WILD-CAUGHT HOUSE SPARROWS WITH WNV, CSLEV, AND HSLEV SERIALLY IN VARYING ORDERS OR CONCURRENTLY IN ORDER TO DETERMINE INTERVIRAL INFECTION KINETICS (VIREMIA AND ANTIBODY RESPONSES) AND HOST FITNESS. LASTLY, PASSIVE TRANSFER OF SLEV (CONTEMPORARY OR HISTORICAL) OR WNV ANTISERA FROM PREVIOUSLY INOCULATED BIRDS WILL BE GIVEN TO NAIVE SPARROWS WITH SUBSEQUENT CHALLENGE BY HETEROLOGOUS VIRUS. THE SIGNIFICANCE OF THIS PROPOSAL LIES IN ITS APPLICATION TO BETTER PREDICT AND MITIGATE FUTURE HUMAN EPIDEMICS FOR BOTH WNV AND SLEV.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $87.2k | 9/3/25 |